Amarin Corp Plc (AMRN)

[Whalatane]

JR. re your comment

t But what COULD happen, is that some script growth in UK/EU, coupled with lower overall operating costs, could show some material Net Income improvements.

Agree, and I think thats what's moving the PPS needle now ...the expectation of at least some script growth in the UK AND lower operating costs .
AMRN is actively working to market Icosapent-ethyl in England /Wales as demonstrated by their participation in the upcoming July 5-7 th HEART UK conference .

I'm not aware of much marketing activity in the EU areas where Icospapent-ethyl ( Vazkepa ) is covered ... Do you ( or anyone reading this ) have any info on that ?
Kiwi